palonosetron and Myocardial-Infarction

palonosetron has been researched along with Myocardial-Infarction* in 1 studies

Other Studies

1 other study(ies) available for palonosetron and Myocardial-Infarction

ArticleYear
Effects of Palonosetron on Perioperative Cardiovascular Complications in Patients Undergoing Noncardiac Surgery With General Anesthesia: A Retrospective Cohort Study.
    Clinical pharmacology and therapeutics, 2015, Volume: 98, Issue:1

    We retrospectively investigated whether palonosetron administered during the induction of general anesthesia is associated with an increased risk of perioperative cardiovascular complications in a single tertiary center cohort consisting of 4,517 palonosetron-exposed patients and 4,517 propensity score-matched patients without palonosetron exposure. The primary endpoint was a composite of perioperative cardiovascular complications, including intraoperative cardiac arrhythmia, intraoperative cardiac death, and myocardial injury within the first postoperative week, and there was no significant difference between the groups (odds ratio [OR] = 1.04; 95% confidence interval [CI] = 0.92-1.19). As secondary endpoints, intraoperative cardioversion, cardiac compression, use of cardiovascular drugs, postoperative hospital stay, and in-hospital mortality showed no differences between the groups. However, the palonosetron group showed decreased intraoperative hypotension (OR = 0.88; 95% CI = 0.79-0.97) and length of postoperative intensive care unit (ICU) stay (4.26 ± 9.86 vs. 6.14 ± 16.75; P = 0.026). Palonosetron did not increase the rate of perioperative cardiovascular complications, and can therefore be used safely during anesthetic induction.

    Topics: Adult; Aged; Anesthesia, General; Antiemetics; Arrhythmias, Cardiac; Cardiovascular System; Case-Control Studies; Female; Humans; Isoquinolines; Male; Middle Aged; Myocardial Infarction; Palonosetron; Perioperative Period; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists

2015